ProstaLin-C®

EUR 40.33 The sales tax depends on the billing address.

ProstaLin-C® is used to support a healthy prostate and bladder function, and as a preventative and supplementary treatment for prostate disorders such as prostatitis, prostatic hyperplasia, and prostate cancer.

One capsule of ProstaLin-C® (450 mg) contains the following ingredients:

  • 150 mg LinumLife (lignans from linseed)
  • 125 mg Biocurcumin (curcuminoid from turmeric)
  • 50 mg Lycopene (tomato extract as a source of lycopene)
  • 32 mg Zinc citrate
  • 550 μg Selenomethionine (0.5% Se)

Take one capsule three times daily with water, before meals. Do not take more tablets than recommended. Do not use, if seal is broken. Store in a cool dry place. Keep out of reach of children. This dietary supplement supports healthy prostate cell function; it does not replace a balanced diet.

Produktdescription

ProstaLin-C is a combination supplement containing LinumLife®, Biocurcumin®, lycopene, zinc citrate, and selenium.

The supplement is used to support a healthy prostate and bladder function, and as a preventative and supplementary treatment for prostate disorders such as prostatitis, prostatic hyperplasia, and prostate cancer.

One ProstaLin-C capsule (450 mg) contains the following

ingredients:
• 150 mg LinumLife (lignans from linseed)
• 125 mg Biocurcumin (curcuminoid from turmeric)
• 50 mg Lycopene (tomato extract as a source of lycopene) • 32 mg Zinc citrate
• 550 μg Selenomethionine (0.5% Se)

ProstaLin-CTM is manufactured in the Netherlands in accordance with the international regulations for the manufacture of medicines, including dietary supplements. The preparation has many biological effects, effects that are also known for the individual ingredients.

ProstaLin-CTM is a combination preparation that contains lignans from linseed, curcuminoid from turmeric, and lycopene from tomato extract, and combines these with zinc citrate and selenium. The preparation is for maintaining a healthy prostate function and for the prevention – and complementary treatment – of prostate disorders.

ProstaLin-CTM has the following effects:

• Neutralizes free radicals due to antioxidative effect in prostate tissue
• Reduces infections and the risk of infection in the prostate and improves urinal flow in the elderly
• Prevents prostatic hyperplasia and cancer in the prostate
• Strengthens the immune system (cellular resistance)

Productinformation

Scientifically-proven effects of the individual ingredients:

LinumLife® is a standardized linseed extract that contains various lignans. Lignans are secondary plant substances with weak phyto-oestrogens and a clear antioxidative effect. The most important lignan in linseed is the so-called secoisolariciresinol diglucoside that is converted into secoisolariciresinol by the intestinal flora and subsequently, due to further metabolic processes, into enterolactone and enterodiol. These lignans benefit not only the general health of cells, but are also extremely valuable in preventing cancer. For example, the published scientific results of a pilot study in 2004 by the German Cancer Research Center in Heidelberg (Germany), recommended linseed and linseed oil for the prevention of breast cancer and bowel cancer. Lignans have also demonstrated a positive effect on benign prostatic hyperplasia (BPH); they apparently balance hormone levels that play a role in the development of BPH. This shrinks the prostate and reduces inflammatory processes. The lignans in LinumLife have been clinically tested, and are safe and easily digestible.

Biocurcumin BCM95® is a patented extract of turmeric that has numerous biological effects. For instance, it has antioxidative, anti-inflammatory, antibacterial, and anti-rheumatic effects. In addition, clear cancer-inhibiting effects have also been described. Unlike normal turmeric extract, the bioavailability of Biocurcumin BCM95 is extremely good (about seven times higher). This means that when only 250 mg of Biocurcumin BCM95 is taken orally, it reaches approximately the same efficacy level in the blood that normally requires approximately 1500 mg of turmeric extract or approximately 37,500 mg of normal curcumin powder. This means that taking Biocurcumin BCM95 rapidly leads to therapeutic concentrations of the important curcuminoid in the blood.

The Biocurcumin BCM95 complex has the following positive distinguishing characteristics:

  • 100% natural extract from turmeric (curcuma longa) without artificial additives
    • Clinical studies show that the bioavailability of BCM95 extract is seven to eight times higher than other curcumin extracts
    • Considerably smaller doses achieve the same effect as high doses of traditional curcumin extracts
    • Powerful antioxidative effect
    • Clinically significant anti-inflammatory properties

Lycopene:

This carotenoid (pigment that gives tomatoes their characteristic red colour) has a pronounced, powerfully antioxidative and cancer-inhibiting effect. Dr Giovannucci of Harvard University is believed to be the founder of lycopene research in relation to prostate cancer. In a major study involving 47,894 men, he examined the relationship between ingesting various carotenoids and retinol on the one hand and the risk of developing prostate cancer on the other (J Natl Cancer Inst, 1995). This study revealed that taking lycopene reduced the risk. Men who consumed tomatoes and tomato-based products several times a week had a 41% smaller risk of developing prostate cancer.

More recent research indicates that lycopene can be used therapeutically too. It seems that lycopene is the dominant carotenoid in our blood and it is not converted into vitamin A. It forms approximately 50% of all carotenoid in the blood and appears to be concentrated mainly in the prostate, as slightly elevated concentrations were detected in the blood near this organ. A recent publication by Kucuk et al. (Urology, 2001) indicated that giving 30 mg lycopene per day to men with localized prostate cancer prior to a planned radical operation resulted in a significant reduction in prostate-specific antigen (PSA) before the operation and a reduced malignancy of the prostate tumour tissue that was surgically removed. ProstaLin-CTM contains about 50 mg of lycopene as a therapeutic dose for patients with prostate disorders.

Zinc:

This trace element supports scores of immune functions, and an inadequate intake of zinc could generally increase our susceptibility to cancer. Zinc is needed in order for many enzymes to work normally, particularly enzymes with an antioxidative effect. A fall in the zinc level in the blood inhibits the NK-cells, the T-helper cells, and even the macrophages of the immune system. Feng et al. have succeeded in proving (Mol Urol, 2000) that a high intracellular zinc level in prostate cancer cells can lead to apoptosis. In addition, Liang et al. (Prostate, 1999) and Iguchi et al. (Eur J Biochem, 1998) have described how zinc can inhibit cancer cell growth in the prostate by influencing the cellular cycle and, moreover, that tumour progression and metastasis formation are linked to a decreased ability to store zinc in the prostate cells. ProstaLin-CTM contains 32 mg of zinc and provides the daily required dose of this trace element.

Selenium:

This mineral, similarly to vitamin E, has a preventative effect with regard to prostate cancer. Research that has gained international fame, carried out by Dr Larry Clark (Br J Urol, 1998) of the University of Arizona, USA, examined whether selenium has a preventative effect with regard to skin cancer. The research examined 1300 men in total. Half of them received 200 micrograms of selenium per day, while the other half received a placebo. The study lasted eight years and, when it ended, Dr Clark realized that skin cancers so common to Arizona were not reduced by selenium, but he noticed that the men in the selenium group had a 50% reduction in the frequency of prostate cancer. Furthermore, the frequencies of lung cancer and colonic cancer in this group were 50% lower than in the comparison group who took a placebo instead of selenium.

Dr Willet of Harvard University (J Natl Cancer Inst, 1998) determined the selenium blood levels of a large number of men and established that lower levels of selenium went hand-in- hand with an increased risk of prostate cancer. This study has also been confirmed by the research group affiliated with Dr Giovannucci (Lancet, 1998).

The National Cancer Institute (NCI) in the USA carried out a study in which the preventative effects of selenium and vitamin E with regard to prostate cancer were tested in a group of 32,000 men. We cannot as yet precisely explain the preventative effect that selenium has with regard to prostate cancer. A plausible hypothesis is the proven effect of selenium on the enzyme glutathione peroxidase. Selenium increases the activity of this enzyme, which has a pronounced, powerful antioxidative effect.

Selenium is normally found in various types of grain and in garlic, particularly if these are cultivated in soil that is rich in selenium. However, the amount consumed in our diets is often insufficient to satisfy the daily requirement of healthy people, let alone that of patients with prostate cancer. The daily quantity needed for the prevention of prostate cancer and as a complementary treatment of prostate cancer is between 400 and 800 micrograms.

 

Recommendations, Supplement facts

Take one capsule three times daily with water, before meals. Do not take more tablets than recommended. Do not use, if seal is broken. Store in a cool dry place. Keep out of reach of children. This dietary supplement supports healthy prostate cell function; it does not replace a balanced diet.